Deals
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The Canadian biotech announced the acquisition of two new pipeline assets that align with its focus on autoimmune and kidney-related disease.
Amidst a chorus of pushback from scientific and health organizations, Philip Morris International’s $1.4 billion offer now has the backing of Vectura Group’s board.
The global biopharmaceutical company said that it is well capitalized with cash, cash equivalents, restricted cash, and investments of as much as $222.8 million as of 30 June 2021.
AbbVie’s Allergan Aesthetics announced it was buying Soliton in a deal worth about $550 million. Now, the Federal Trade Commission has requested additional information about the deal.
Messenger RNA has become the life sciences hero of the decade. The lynchpin in the fight against COVID-19, companies are taking mRNA technology to new heights.
BioLife will obtain all of the outstanding shares of Sexton that it doesn’t already own for $24 million in consideration for 506,382 newly issued shares of BioLife common stock.
The acquisition of OtiTopic will boost the company’s new strategy and potentially address a significant unmet medical need in more than 83 million people in the U.S. with myocardial infarction.
The deal will give EQRx a pre-transaction enterprise value of $3.65 billion and an immediate $1.8 billion in cash that will be used to advance the development of the company’s pipeline.
Under the terms of the agreement, Bayer is paying $1.5 billion upfront and up to $500 million in various milestone payments.
Show me the money! This week’s who’s who of IPOs and financing rounds in the biopharma world.